800results about "Dipeptide ingredients" patented technology

The invention provides a whey protein deep hydrolysate with low sensitization and an allergy relieving effect as well as a preparation method and application of the whey protein deep hydrolysate. According to the method, the alkaline protease, the neutral protease and the glutamyltransferase are sequentially used for carrying out first enzymolysis, second enzymolysis and third enzymolysis on the whey protein raw material, and the whey protein hydrolysate which is low in molecular weight, good in taste, good in digestion and absorption performance, low in sensitization and capable of effectively relieving allergic reaction of the organism is obtained.

The invention discloses a novel HIF-2 alpha proteolysis targeting chimera 1 as well as a preparation method and application thereof, the structural formula 1 of the novel HIF-2 alpha proteolysis targeting chimera 1 is shown in the specification, and the obtained novel HIF-2 alpha proteolysis targeting chimera 1 has good proliferation inhibition activity on kidney cancer 786-O cells. The novel HIF-2alpha protein hydrolysis targeting chimera designed by the invention is novel in structure, few in preparation route process steps, easy to obtain raw materials, suitable for industrial production and good in application value.

The invention relates to the technical field of pharmaceutical preparations, in particular to a stable perindopril amlodipine tablet and a preparation method thereof, and the tablet comprises the following components in percentage by weight: 5.0% of arginine perindopril; 3.5% of amlodipine besylate; 20%-40% of pregelatinized starch; 40%-68% of a microcrystalline cellulose colloidal silicon dioxide compound; 2.5%-6% of a disintegrating agent, wherein the disintegrating agent is selected from one or more of ion exchange resin, sodium alginate and croscarmellose sodium; the pregelatinized starch and the microcrystalline cellulose colloidal silicon dioxide compound are selected as main diluents, so that the Maillard reaction possibly occurring between the lactose and the active pharmaceutical ingredients is completely avoided, the problem of increase of related substances is fundamentally solved, and the stability and the safety of the product are remarkably improved.

The present application relates to a kind of dipeptide derivative compositions and its preparation method and purposes, the composition includes (a) formula I compound, (b) glycine and (c) antioxidant, the composition has good adjuvant compatibility, the impurity content of lyophilized preparation prepared according to the composition is low, under high humidity, strong light and low temperature storage condition, all have good stability.

The present invention discloses therapeutic compounds capable of targeting a wide range of tumor cells. The disclosure is further directed to compositions comprising the therapeutic compounds, methods for producing the therapeutic compounds, and methods for treating cancer comprising administering the therapeutic compounds.

The invention relates to the technical field of medicine preparation, and provides a bortezomib nano composition, and the bortezomib nano composition comprises the following components: bortezomib, albumin and a medium. The bortezomib nano composition can be delivered in a targeted manner, is low in toxicity and stable, and provides a new strategy for treatment of multiple myeloma.

The present disclosure provides bifunctional compounds as HPK1 degraders via the ubiquitin proteosome pathway and methods for treating diseases modulated by HPK1. The present invention provides novel bifunctional compounds for proteolytically degrading hematopoietic progenitor kinase (HPK1) and methods for treating diseases modulated by HPK1. HPK1 can be targeted for degradation, thereby providing therapeutic opportunities in enhancing anti-tumor immunity and increasing responses to checkpoint receptor blockade.

The invention discloses multi-component inulin hydrogel as well as a preparation method and application thereof, and belongs to the technical field of nano materials and medicines.The multi-component inulin hydrogel is characterized in that a medicine L-alanyl-L-glutamine contributing to intestinal mucosa repair is entrapped in the inulin hydrogel; the multi-component inulin hydrogel has the advantages that the multi-component inulin hydrogel is prepared from the inulin and composite nanoparticles (namely mesoporous polydopamine-gallium composite nanoparticles) composed of an active oxygen scavenger polydopamine and an antibacterial agent gallium ions, the repairing capacity on intestinal barriers is further enhanced, and the prepared multi-component inulin hydrogel can be used for effectively treating inflammatory bowel diseases and non-alcoholic steatohepatitis.

The invention relates to the technical field of cosmetics, in particular to composite polypeptide liposome hydrogel as well as a preparation method and application thereof.Composite polypeptide is wrapped by an ethosome technology, the stability of a liposome membrane is enhanced through surface modification of whey protein peptide on liposome, and the stability of the liposome membrane is enhanced through non-ionized polymer hydrogel. The composite polypeptide liposome is anchored in a hydrogel grid, so that the stability of the polypeptide liposome in formula application is further improved, the transdermal permeation absorption of polypeptide is more effectively promoted, and the retention amount of active matters in a skin layer is increased.

The tumor stroma, which accounts for a large portion of the tumor mass, is an attractive target for the delivery of diagnostic and therapeutic compounds. Here, we focus specifically on a subpopulation of stromal cells known as cancer-associated fibroblasts, which are present in over 90% of epithelial cancers, including pancreatic, colon, and breast cancers. Cancer-associated fibroblasts are characterized by high expression of FAPs, which are undetectable in adult normal tissues but are associated with poor prognosis in cancer patients. The present invention provides small molecule radiopharmaceuticals and imaging agents based on FAP-specific inhibitors.

The invention belongs to the technical field of biological medicine, and particularly discloses application of a small molecule compound DRP (Dalicyclic Polymorphism)-104 in preparation of a medicine for treating uveal melanoma. The molecular formula of the DPR-104 is CHNO; an in-vitro experiment proves that the small molecular compound DPR-104 can effectively kill uveal melanoma cells, specifically, proliferation of the uveal melanoma cells is inhibited in an in-vitro concentration-dependent manner, and apoptosis of tumor cells is promoted; animal experiments prove that DPR-104 can effectively kill uveal melanoma in vivo and enhance the effect of uveal melanoma radiotherapy. On the basis, the invention provides a brand-new treatment medicine for uveal melanoma, the treatment effect can be effectively improved, and the life of a patient can be prolonged.

Use of an active peptide in the manufacture of a product to improve the skin barrier and promote collagen expression and / or increase skin elasticity and suppleness and / or reduce wrinkles, characterized in that the active peptide has the structural formula HA-OH, wherein A comprises at least two amino acid residues, and the amino acid residues comprise at least one from Hyp, Gly, Pro and Ala.

A food medicine for reducing blood uric acid and treating gout is characterized in that celery seeds, celery, mulberry fruits, mulberry leaves, sea buckthorn fruit powder, dandelions, rhizoma polygonati, poria cocos and beach kidney grass serve as a basic formula; the auxiliary materials comprise one, several or all of a plurality of formula combinations of ramulus mori, lycium ruthenicum, radix puerariae, Chinese yam, clerodendranthus spicatus, lysimachia christinae hance, acanthopanax, anserine, astragalus membranaceus, purslane, herba cepbalanoplosis segeti, galangal, hovenia dulcis thunb, astragalus membranaceus, luteolin, uric acid-reducing edible probiotics and the like, and are used for treating hyperuricemia and gout.

The invention discloses an application of bortezomib in preparation of a medicine for resisting grouper iridovirus. Researches show that bortezomib has a remarkable inhibiting effect on grouper iridovirus, and is low in cytotoxicity and good in safety. The bortezomib can obviously reduce the fluorescence signal intensity of virus protein, inhibit the transcriptional level of main capsid protein MCP and envelope protein VP19 of the virus and reduce the copy number of DNA and mRNA of the virus; the bortezomib can effectively inhibit grouper iridovirus infection and effectively block synthesis of virus protein, so that efficient inhibition of grouper iridovirus infection is achieved, and along with prolonging of virus infection time, bortezomib can also remarkably inhibit virus gene transcription, protein synthesis and genome replication. Therefore, bortezomib not only can effectively prevent and treat grouper iridovirus infection, but also has the characteristics of high specificity, low toxicity, remarkable antiviral effect and the like, and also has important application value in prevention and control of iridovirus-related diseases in aquaculture industry.

The invention belongs to the field of medicines, and relates to a perindopril amlodipine solid preparation as well as a preparation method and application thereof. In the prior art, when an in-vitro dissolution behavior of an imitated medicine of perindopril and amlodipine tablets is investigated, it is found that the release behaviors of the perindopril and amlodipine tablets are difficult to keep consistent with those of an original developed preparation at the same time, so that the safety and effectiveness of the imitated medicine are not guaranteed. A large number of experiments find that the particle size distribution and the water content of the microcrystalline cellulose are controlled, so that the in-vitro dissolution curve of the perindopril amlodipine solid preparation is similar to that of an imported original development agent produced by an original research company, the possibility of bioequivalence with the original development agent is improved, and the drug consistency evaluation requirement is met.

The invention discloses a pyrazolecarboxamide compound and application of the pyrazolecarboxamide compound. Specifically, the invention discloses a compound shown as a formula I or a pharmaceutically acceptable salt thereof. The compounds of the present invention are IL-17 small molecule modulators, and can be used for the treatment or prevention of IL-17 mediated diseases, such as autoimmune diseases.

The present invention pertains to a cyclic(glycine-proline)-enriched peptide composition and the use thereof particularly for ameliorating neurological conditions or fibrosis. The present invention furthermore pertains to a method for obtaining a peptide composition enriched in cyclic(glycine-proline), the method comprising providing a collagen hydrolysate enriched in gly-pro-x tripeptides, and heat-treating the collagen hydrolysate to allow cyclization of at least part of the gly-pro-x tripeptides to cyclic(glycine-proline).

To provide non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides.SOLUTION: The dolastatin analogs may have a wide range of possible functional groups, but typically have at least one oxime, carbonyl, dicarbonyl, and / or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and / or hydroxylamine group.SELECTED DRAWING: Figure 4

Methods and corresponding uses are provided for treating disease in patients involving the use of sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] to improve drug resistance, including resistance to proteasome inhibitors and immunomodulatory imide drugs. The disease may be, for example, relapsed / refractory multiple myeloma.

To provide a compound that can be readily synthesized, exhibits antibacterial activity against Porphyromonas gingivalis being a pathogenic bacterium of periodontitis, with greater specificity, and exhibits increased stability against esterase as well as reduced cytotoxicity.SOLUTION: The present invention provides a compound represented by a general formula (1) [where R1 is a halogen atom or a nitro group, and R2 is an alkoxy group or an acylamino group] or a salt thereof or a solvate thereof.SELECTED DRAWING: None

The invention relates to a Pan KRAS protein degradation agent as well as a preparation method and application thereof. Specifically, the compound provided by the invention has a structure as shown in a formula I. The invention also discloses a preparation method of the compound and application of the compound in prevention and / or treatment of KRAS mutation related diseases.

Disclosed herein are compositions and methods for promoting weight loss and / or preventing obesity; enhancing athletic performance / endurance; enhancing muscle function; enhancing cognitive function; promoting weight management; enhancing cardiovascular health; enhancing blood flow; reducing inflammation; and / or regulating immunity.In certain embodiments, the disclosed method comprises administering to subject the composition comprising the combination of dileucine and paraxanthine, and / or dileucine and L-arginine, and / or dileucine and leucine.

The present invention relates to a ginseng peptide and a preparation method and application thereof, belonging to the field of biotechnology. The present invention provides a ginseng peptide, wherein the ginseng peptide comprises a characteristic peptide having an amino acid sequence of at least one of LY, MM, LR, AP, LAR, RLDFR, SALAFR, LLLLGH and LLLLLHG. The present invention obtains ginseng peptides by treating fermented ginseng residue, and identifies the characteristic peptides containing the amino acid sequences of LY, MM, LR, AP, LAR, RLDFR, SALAFR, LLLLGH and LLLLLHG in the ginseng peptides by HPLC-MS / MS. The present invention confirms through experiments that ginseng peptides and fermented ginseng hydrolysates containing ginseng peptides have excellent efficacy in inhibiting the differentiation of bone marrow mononuclear cells into osteoclasts, can improve hormone-induced osteoporosis, and can be applied to products for improving osteoporosis and its related symptoms.

The present invention relates to a compound, aprocitentan, {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yl-oxy)-ethoxy]-pyrimidin-4-yl}-sulfamide; and its use as an endothelin receptor antagonist in a method of treating hypertension, including resistant hypertension in a subject, the use comprising administering to a subject in need thereof a pharmaceutical composition comprising a clinically effective amount of aprocitentan or a pharmaceutically acceptable salt thereof. 【Chemical 1】 TIFF2025519101000003.tif76153

The present invention relates to a dipeptide derivative composition, a preparation method therefor, and use thereof. The composition comprises (a) a compound represented by formula I, (b) glycine, and (c) an antioxidant. The composition has good auxiliary material compatibility. A freeze-dried formulation prepared from the composition has low impurity content and features good stability under high humidity, strong light, and low temperature storage conditions.

The present application discloses lactam ring compounds and uses thereof, which have a rapid antidepressant effect.

An object of the present invention is to provide a small molecule compound (IL-17 activity inhibitor) having a more potent inhibitory effect on IL-17 activity than conventional compounds. The IL-17RA inhibitor of the present invention is, for example, a small molecule compound surrounded by Phe60, Gln87, Asp121, Pro122, Asp123, Gln124, Asp153, Cys154, Glu155, Lys160, Pro164, Cys165, Ser167, Ser168, Gly169, Ser170, Leu171, Trp172, Asp173, Pro174, Pro254, Phe256, Ser258, Cys259, Asp262, Cys263, Leu264, and His266, which are contained in the extracellular domain of human interleukin-17 receptor A (IL-17RA). The compound contains a compound having the effect of inhibiting the binding of interleukin-17A (IL-17A) to IL-17RA in humans, etc., or a pharmaceutically acceptable salt, solvate, or prodrug thereof, which can bind to IL-17RA through non-covalent interactions, including van der Waals forces acting between at least 13 of these amino acid residues in the space defined by the compound, and preferably further including at least one type of intermolecular interaction selected from the group consisting of ionic bond, hydrogen bond, C-H-π interaction, and hydrophobic interaction acting between predetermined ones of the amino acid residues.

The present invention relates to a use of Cyclo-His Pro (CHP) alone or zinc and Cyclo-His Pro (zinc and CHP, Cycloz) for inhibiting muscle loss or alleviating muscle function decline caused by anti-obesity drugs. More specifically, the present invention provides a pharmaceutical composition and a health functional food composition, which when administered in combination with an anti-obesity drug, exhibit an effect of inhibiting the anti-obesity drug-induced side effect of muscle loss while maintaining a weight loss effect, and exhibit an effect of preventing, alleviating, or treating sarcopenic obesity, and a method for inhibiting muscle loss or alleviating muscle function decline caused by an anti-obesity drug and a method for preventing, alleviating or treating sarcopenic obesity using same.

To provide a composition for preventing, ameliorating or treating a disease caused by protein nitration comprising a peptide with terminal tyrosine as an effective component.SOLUTION: A peptide with terminal tyrosine has an excellent effect of inhibiting protein nitration and also an excellent effect of preventing, ameliorating or treating disease symptoms in chronic immobilization stress-induced depression / cognitive impairment model, Alzheimer's disease model, epileptic seizure model, stroke model, type 2 diabetes model, acute renal failure model, or hyperammonemia model.SELECTED DRAWING: None